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Both procainamide and lidocaine are useful for 
acutely treating cardiac arrhythmias, and procain-
amide can be useful in chronic antiarrhythmic regi-
mens. Successful management of cardiac arrhythmias 
requires knowledge of: 1) the mechanism and nat-
ural history of the arrhythmia, 2) the physiologic 
state of the patient, and 3) the cardiac effects, phar-
macodynamics, and general pharmacology of the 
antiarrhythmic drugs. 
Although often done, it is foolhardy to under-
take treatment of a cardiac arrhythmia without a 
precise diagnosis. The rationalization for such an un-
dertaking frequently is that, no matter which of sev-
eral possible arrhythmias is at hand, the treatment to 
be initiated would be beneficial or at least not harmful 
for any. This rationalization is often invoked to avoid 
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the considerable effort which may be required in or-
der to precisely diagnose the nature of the arrhyth-
mia. There are many specific cases where one not 
only treats a harmless arrhythmia, or, by not making 
a diagnosis, fails to use the correct therapy, but also 
employs a therapy which is actually harmful. Figure 
1 shows an example of unnecessary therapy on the 
basis of an error in diagnosis. This patient had occa-
sional ventricular premature depolarizations (VPD's). 
T he VPD's were often followed by an aberrantly 
conducted beat of supraventricular origin. These 
couplets of wide QRS's were incorrectly considered 
to be salvos of VPD's and were treated with lido-
caine. In fact, the patient had no indication for anti-
arrhythmic drug therapy at all. As luck would have 
it, lidocaine caused undesirable central nervous sys-
tem effects in this patient. As mentioned above, ther-
apy may be not only inappropriate but also damag-
ing. For example, patients with atrial flutter with 
variable A-V conduction not infrequently show wide 
aberrant beats. In intensive care units, these are often 
mistakenly called VPD's. The fact that a non-stan-
dard bipolar chest lead is used for monitoring may 
obscure the fact that the beat has a RBBB config-
uration, a finding which might lead the physician to 
suspect aberrant conduction. Also, treatment may be 
initiated on the basis of observation of the rhythm 
on the oscilloscope screen. Thus, the physician may 
overlook the typical group beating of the Gouaux-
65 
66 
. I -~ --
-
-
-
HRA 
I 
-
l 
BIGGER AND GIARDINA: LIDOCAINE AND PROCAINAMIDE 
j 
.. 
... 
-
j 
' 
Fig. ]- Incorrect interpretation of rhythm leading to unnecessary therapy. The upper panel shows lead I of the ECG which was 
incorrect ly interpreted as salvos of VPD'~, and on this basis lidocaine was begun. 
The lower panel shows recordings from high right atrium (HRA), the bundle of His (H BE), and lead I of the ECG. Actually, 
the rhythm was occasional VPD's with concealed retrograde conduction resulting in aberrant conduction of the subsequent beat 
(LBBB configuration). 
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Ashman phenomenon which would have been more 
obvious in analyzing a paper recording. This com-
bination of errors in the intensive care unit can 
cause aberrant beats to be treated with lidocaine. 
Lidocaine can slow the atrial rate and enhance A-V 
conductivity, leading to a striking increase in ven-
tricular rate. Lidocaine in these circumstances has 
caused atrial flutter to conduct with a 1 : 1 A-V ratio 
and has produced ventricular rates of nearly 300 per 
minute. If the heart is hemodynamically impaired, 
rapid heart rates caused in this way can be cata-
strophic. Other examples could be given, but these 
two suffice to underscore the importance of obtaining 
a correct diagnosis of the arrhythmia before embark-
ing on a therapeutic course. 
Even after precise identification, obviously, not 
all arrhythmias deserve treatment with suppressant 
antiarrhythmic drugs. Many arrhythmias do not de-
serve any therapy whatsoever. The past decade of 
coronary care unit experience has taught us a great 
deal about the natural history and indications for 
treating arrhythmias which arise between 4 and 72 
hours after onset of symptoms in acute myocardial 
infarction. A great error which has become a na-
tional epidemic has been the unjustifiable extrapola-
tion of the CCU experience to the first two hours of 
infarction or of the late postinfarction period. At both 
of these times the pattern arrhythmias, their meaning, 
or their response to therapy seem to be very different 
from arrhythmias encountered in the CCU and, at 
present, less well characterized. Even worse, there is 
a widespread tendency in recent years to use the same 
criteria for treating arrhythmias in other etiologic 
forms of heart disease as those used in acute myo-
cardial infarction. In most forms of heart disease, our 
knowledge of the meaning and natural history of ar-
rhythmias is even more rudimentary than our knowl-
edge of arrhythmias in various stages of coronary 
heart disease. However, in many diseases, it is abun-
dantly clear that arrhythmias do not need treatment 
even though the same ECG pattern would dictate 
therapy in acute myocardial infarction. 
Once an arrhythmia is identified and the need 
for treatment established, the regimen of therapy 
may or may not require a specific antiarrhythmic 
drug. Arrhythmias encountered outside the coronary 
care unit very often are caused or seriously aggra-
vated by non-cardiac factors such as electrolyte, acid-
base, or blood gas derangements or drug toxicity. 
When initially evaluating any cardiac arrhythmia, the 
physician should consider the many possible non-
cardiac causes and institute the appropriate clinical 
and laboratory investigations to identify these, even 
though temporary emergency therapy is required im-
mediately. Not only will correction of non-cardiac 
causes usually control the arrhythmia but also ar-
rhythmias generated by electrolyte imbalance or 
blood gas derangement may be highly resistant to 
"specific" antiarrhythmic drugs like procainamide or 
lidocaine. 
When a drug is finally selected to treat an ar-
rhythmia, the goal is to maintain the plasma concen-
tration above the minimum effective concentration 
without inadvertently producing toxic concentrations. 
To successfully achieve this goal requires a consid-
erable knowledge about the pharmacokinetics, me-
tabolism, and excretion of the drugs utilized. 
It is our purpose to discuss briefly the clinically 
relevant electrophysiologic properties, clinical usage, 
pharmacodynamics, and toxicity of procainamide 
and lidocaine. 
Electrophysiologic Properties. The following 
are a few clinically relevant electrophysiologic effects 
of procainamide and lidocaine. 
Lidocaine. Lidocaine is a Group II antiarrhyth-
mic drug. It suppresses automaticity in cardiac Pur-
kinje fibers by increasing the potassium conductance 
of the sarcolemma but does not significantly alter 
threshold voltage. It shortens action potential dura-
tion and refractoriness in Purkinje fibers and ven-
tricular muscle but has practically no effect on atrial 
tissues . It does not alter conduction velocity or re-
sponsiveness very much in either normal atrial or 
normal ventricular tissues. Under certain circum-
stances, lidocaine can improve conduction or reverse 
conduction block in ventricular tissues. Lidocaine 
depresses sinus node function less than procainamide. 
Rarely, it has been reported to suppress sinus func-
tion, usually in older patients, particularly with in-
ferior myocardial infarction and/ or preexisting signs 
of sinus node dysfunction. Lidocaine has little effect 
on atrial arrhythmias as might be predicted from its 
lack of effect on atrial tissues from normal animals. 
The drug can, but does not always, cause slight slow-
ing of atrial rate in atrial flutter. Also, lidocaine 
causes no change or decrease in A-V conduction 
time and A-V refractoriness. Since the drug does not 
prolong conduction in the ventricular tissues, it does 
not prolong the QRS, and since it does not prolong 
action potential duration in the ventricles, it does not 
prolong the QT. It is still not clear how lidocaine 
abolishes reentrant ventricular arrhythmias in man. 
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Our studies to date suggest that it may do so either 
by improving conduction throughout the reentrant 
circuit or by blocking conduction in abnormal com-
ponents of the circuit without affecting normal com-
ponents. 
Procainamide. Procainamide (like quinidine) is 
a typical Group I antiarrhythmic drug. It suppresses 
automaticity and moves the threshold voltage of heart 
muscle toward zero. Also, it lengthens action poten-
tial duration and lengthens the refractory period of 
atrial and ventricular cell types. It slows conduction 
in the atrium, A-V node, and ventricle and decreases 
membrane responsiveness of atrial and ventricular 
fibers. Many of these actions are reflected in the 
ECG. Procainamide does not usually affect the sino-
atrial rate in intact man, but it can cause dramatic 
slowing of sinus rhythm in patients with derange-
ments of sinus node function. This drug often causes 
minimal flattening and widening of the P wave. The 
atrial rate is slowed by procainamide in atrial fibril-
lation and flutter, and high concentrations will con-
vert these rhythms to sinus rhythm. A direct action 
of procainamide is to slow A-V conduction and in-
crease the refractoriness of the A-V conducting sys-
tem; the magnitude of this effect is quite variable 
from patient to patient under similar conditions and 
is modified by many other variable factors. Adminis-
tration of procainamide to treat VPD's caused by 
digitalis toxicity may unpredictably produce severe 
A-V conduction disturbances. Slowing of conduction 
in the His-Purkinje system and in ordinary ventricu-
lar muscle caused by this drug is reflected in a wid-
ening of the QRS interval. In a given patient, QRS 
width changes usually increase linearly as a function 
of plasma drug concentration. The changes in re-
polarization produced by procainamide usually cause 
prolongation of the QT interval and alteration in T 
wave contour. The rather reliable change in QRS 
and QT intervals has proved quite useful in estimat-
ing therapeutic and toxic cardiac effects during ther-
apy. The profound changes procainamide causes in 
conduction, responsiveness, and refractoriness of ven-
tricular tissues no doubt underly its impressive abil-
ity to suppress VPD's or ventricular tachycardia. 
Our recent experiments in man suggest that as the 
plasma concentration of this drug rises, it causes a 
steadily increasing depression of conduction in a ven-
tricular reentrant circuit until conduction fails alto-
gether and the arrhythmia is abolished. 
Clinical Use. Lidocaine. Lidocaine is not effec-
tive against a wide variety of cardiac arrhythmias, 
being most useful in combatting ventricular arrhyth-
TABLE 1. 
Effectiveness of Lidocaine and Procainamide Against Cardiac Arrhythmias* 
ARRHYTHMIA LIDOCAINE PROCAINAMIDE 
# of Success /# of Cases # of Success /# of Cases 
SUPRA VENTRICULAR: 
Atrial premature depolarizations 15 / 31 (48 %) 8/ 13 (62 %) 
Paroxysmal supraventricular tachycardia 5/ 11 (46 %) 28 / 40 (70 %) 
Supraventricular tachycardia with A-V block 0/ 4 
Atrial flutter 0 / 11 ( 0%) 14 / 53 (26 %) 
Atrial fibrillation 3/ 41 ( 7%) 73 / 215 (34 %) 
A-V junctional premature contractions 4/ 8 (50 %) 9/ 13 (69 %) 
Non-paroxysmal A-V junctional tachycardia 0 / 7 ( 0%) 26 / 33 (79 %) 
Unspecified supraventricular tachycardia 3/ 9 (33 %) 14/ 23 (61 %) 
Total: 30 / 122 (25 %) 172 / 390 (44%) 
VENTRICULAR: 
Ventricular premature contractions 389 / 495 (79 %) 210/ 244 (86%) 
Ventricular tachycardia 48 / 69 (70 %) 98 / 122 (80 %) 
Total: 437 / 564 (77 %) 308 / 366 (84 %) 
* A comparison of clinical effectiveness of lidocaine and procainamide against supraventricular and ventricular arrhythmias. 
Calculations are based on a review of the literature up to 1972 and include arrhythmias that were completely suppressed or at least 
90% improved after drug therapy. The percentage was not determined where total cases were less than five. 
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mias. It is practically worthless against atrial flutter 
or fibrillation (Table 1); the rare instances in which 
it appears to abolish one of these rhythms may only 
be due to coincidence, or to indirect effects. Lido-
caine is also, as a rule, ineffective against atrial or 
A-V junctional tachycardias unless they are caused 
by digitalis excess. Of course, lidocaine is highly effec-
tive against ventricular arrhythmias arising in many 
circumstances, but it is limited to relatively short-
term use because it must be administered paren-
terally. 
It should be emphasized that there is consid-
erable difference in electrophysiologic action between 
procainamide and lidocaine, and it is common to see 
an arrhythmia that is resistant to one, submit to the 
other. 
Procainamide. Procainamide is an antiarrhyth-
mic drug of broad spectrum, effective against a wide 
variety of atrial , A-V junctional, and ventricular ar-
rhythmias (Table 1). In general , higher plasma con-
centrations are required to convert or prevent atrial 
fibrillation than those needed to control ventricular 
arrhythmias. Early in its use, this fact led to the mis-
taken impression that the drug was ineffective against 
atrial arrhythmias. However, as will be discussed 
later, procainamide has a short half-life which means 
to continuously maintain plasma concentrations ef-
fective against atrial arrhythmias requires large doses 
every six hours . Large doses may produce toxic peak 
concentrations and necessitate more frequent dosing, 
a change which is usually inconvenient for the pa-
tient. This drug is a poor choice against ventricular 
arrhythmias in patients with severe A-V conduction 
disturbances because it may worsen conduction. Al-
though it can be effective against many digitalis-toxic 
arrhythmias, its actions in this circumstance are too 
unpredictable to warrant its use. 
Prophylaxis. In very recent years, studies have 
evaluated prophylactic use of procainamide or lido-
caine, as well as other antiarrhythmic drugs, in the 
CCU. These studies, conducted in first-rate univer-
sity hospitals, fail to show a decrease in mortality in 
the treated versus the control group. This might be 
expected since patients with heart failure, shock, 
sinus bradycardia, A-V block, or arrhythmias re-
quiring immediate treatment were not admitted to 
the studies. Furthermore, these CCU's were all well-
staffed so that sophisticated hospital-based physicians 
were almost instantly available to analyze and treat 
arrhythmias which developed in either the placebo 
or drug-treated group. It would seem that a pa-
tient in a university hospital CCU has little to 
gain from prophylactic therapy. On the other hand, 
a patient residing in any one of the many community 
hospital CCU's in this country where the staff may 
be less plentiful or well-trained and the patient's 
physician is based in his office practice, might have 
a great deal to gain from routine prophylaxis. Pro-
phylaxis might prevent harmful results where pre-
monitory arrhythmias were overlooked. However, 
routine prophylaxis in every case of myocardial in-
farction might increase the morbidity and mortality 
in patients with cardiac failure or shock, or those 
with bradyarrhythmias or conduction defects. Thus, 
even in community hospitals, the case for routine 
prophylaxis in acute myocardial infarction is not en-
tirely clear. 
Prophylaxis for arrhythmias in ambulatory, ap-
parently well patients with coronary heart disease is 
even less well-grounded than prophylaxis in acute 
myocardial infarction. Several pertinent facts are 
emerging. First, VPD's are extremely common in 
asymptomatic coronary heart disease patients. Sec-
ond, middle-aged men who have frequent VPD's 
( > 10 VPD's per 1,000 beats) or sustained relative 
bradycardia have a much higher incidence of sud-
den death in follow-up periods than their peers with-
out one of these two rhythm disturbances, even 
though neither group has clinically evident coronary 
heart disease. What is not clear is whether any avail-
able drug can significantly and persistently reduce 
the incidence of these arrhythmias for long periods 
of time without undue undesirable effects. Neither is 
it clear that, if one could alter these arrhythmias that 
are correlated with sudden death, the incidence of 
sudden death would be reduced. Thus, at present, 
prophylaxis in such a population is highly experi-
mental and should be controlled since we do not 
even know that prophylaxis would do more good 
than harm. 
Another related area of current interest arises 
from the fact that patients who die from arrhythmias 
during early stages of acute myocardial infarction 
or ischemia probably suffer from either ventricular 
fibrillation or bradyarrhythmias. It has been sug-
gested that patients who are known to be at risk to 
myocardial ischemia, that is, patients with known 
coronary heart disease, carry syringes containing 
lidocaine and/ or atropine. These patients would be 
advised, on experiencing symptoms of myocardial 
ischemia, to inject their drug intramuscularly and 
come to the hospital. Again , with the evidence avail-
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able at present, we are not certain that such a course 
of action would not be more harmful than helpful, 
and such therapy cannot be recommended for more 
than controlled trials. However, it is reasonable to 
urge immediate contact between the patient with cor-
onary heart disease who has a change in symptoms 
and the health care system. Analysis of the ECG 
either transmitted by telephone or obtained by a 
medical team invading the community would allow 
early specific treatment on the basis of the arrhyth-
mias encountered in the individual patient. Some 
variant of this method would seem greatly prefer-
able to self-injection of drug or drugs initiated on 
the basis of symptoms alone without regard for the 
presence or type of rhythm disturbance. 
Pharmacodynamic Considerations. Particularly 
in treatment of acute arrhythmias, one of the most 
important aspects of antiarrhythmic drug therapy 
is pharmacodynamics. It is necessary to maintain 
the plasma drug level above the minimum effective 
concentration (MEC) because life-threatening ar-
rhythmias may emerge when plasma concentra-
tions dip below this level. Also, the rate at which 
MEC is achieved may be quite important. Knowl-
edge of drug kinetics is even necessary in order to 
assess the effectiveness of the drug being used. Lack 
of a consummate knowledge of pharmacodynamics 
often leads physicians to conclude that a particular 
drug is ineffective in combatting a particular ar-
rhythmia. In actuality, this conclusion is often 
incorrect because the physician is unaware of the 
expected time course of drug action and thus evalu-
ates drug effectiveness at an inappropriate time. 
Since many of the arrhythmias treated in emergency 
situations, for example, acute myocardial infarction, 
are short-lived, the need for antiarrhythmic drug 
therapy is brief. Usually, a few days of such therapy 
is sufficient. When discontinuing or interrupting the 
antiarrhythmic drug therapy under such circum-
stances, knowledge of the expected course of elimi-
nation is vital. This knowledge allows maximum 
intensity of observation at appropriate times without 
wasting effort on unnecessarily intense vigilance at 
inappropriate times. 
Lidocaine. Lidocaine is only used parenterally. 
This drug is very popular in treating acute ventric-
ular arrhythmias where it is usually given as a 
sudden intravenous injection. If the arrhythmia re-
quires treatment for a few days, constant-rate IV 
infusion is employed. Intramuscular injections of a 
special 10% formulation of lidocaine is being studied 
by our group and others for possible use against 
arrhythmias. 
Brief IV injection. Empirical trial has deter-
mined that IV lidocaine doses of 0.5 to 1.5 mg per 
kg body weight can be repeated every three to five 
minutes until a 200 to 300 mg dose is reached. 
This method is usually safe. The time course of 
plasma lidocaine after an IV injection is shown in 
figure 2. Several features of interest can be noted. 
First, the lidocaine concentration rapidly drops be-
low the MEC ( 15-40 minutes), and the arrhythmia 
being treated may return. The early rapid drop 
(t112 = 9 minutes) in concentration is due to distribu-
tion of the drug into its large apparent volume of 
distribution (Vn = 120 liters). After distribution, the 
rate of elimination slows and is accomplished by a 
combination of renal excretion and hepatic metabo-
lism. The hepatic metabolism of lidocaine is so rapid 
that under ordinary circumstances, less than 5 to 
10% of lidocaine is excreted unchanged by the kid-
ney. A note of caution about repeated IV injections 
or injections during infusions: the volume of distri-
bution is partially filled with drug under these cir-
cumstances, and an unexpectedly large increase in 
plasma concentration may occur. 
Intravenous constant-rate infusion. This mode 
of therapy is commonly used. Figure 2 shows the 
time course of the rise in plasma lidocaine when 
infusion is begun without prior doses. Because the 
MEC for lidocaine is usually so low ( 1 to 2µ,g per 
ml) and the elimination t112 so short ( 1.5 to 2 
hours), the plasma concentration usually rises to 
MEC within an hour. If elimination of lidocaine 
is normal, a simple, empirical rule can be applied 
to estimate the plasma lidocaine concentration at 
steady state-the infusion rate of lidocaine in µ,g per 
minute per kg body weight divided by 10 equals 
the plasma concentration of lidocaine in ,µ,g per 
ml, for example, an infusion of 30 µ,g per minute 
per kg body weight should produce a plasma 
concentration of 3.0 µ,g per ml at steady state. 
Like any drug with first order kinetics, 90% of 
the steady state value is achieved in 3.3 times 
the t112 . Most commonly, lidocaine infusions are 
given following one or more IV injections as shown 
in figure 3. Since the elimination t112 of lidocaine 
is fairly brief, plasma lidocaine changes fairly rapidly 
to a new steady state when IV infusion rate is 
increased or decreased and falls rapidly when an 
infusion is discontinued. Low cardiac output is as-
sociated with reduced hepatic blood flow and a 
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Fig. 2- Time-plasma concentration course of lidocaine and procainamide produced by sudden 200 mg intravenous injection (left) 
and constant-rate intravenous infusion (right). 
After IV injection of either drug (lef t) , the early, rapid fall in plasma drug concentration is due to distr ibution of drug into its 
large apparent volume of distribution (Vn). A slower late phase of disappearance is seen which is due to elimination of the drugs 
by a combination of hepatic metabolism and renal excretion. The half-time for elimination (t u 2e) is 1.5 hours for lidocaine and 3.5 
hours for procainamide. 
At right, the plasma concentration during and after a 12-hour constant infusion of procainamide and lidocaine into a 70 kg 
pat ient. The infusion rate was selected so that after an infinite amount of time, the plasma concentration of each drug would be 
4 µg/ ml. For Jidocaine, t 112e = 1.5 hours , V n = 120 liters , and infusion rate = 52.8 µg / min / kg body weight. For procainamide, 
t u,e = 3.5 hours , Yn = 140 liters, and infusion rate = 26.4 µg / min / kg body weight. Primarily due to its longer elimination half-life, 
a much slower rate of procainamide infusion is required to produce a 4 µg / ml steady-state plasma concentration. Because of its 
longer t u 2e, procainamide takes longer to achieve 90% of its steady-state plasma concentration (11.6 hours) than lidocaine (5.0 hours). 
Also, the plasma concentration of procainamide falls slower after discontinuing the infusion. 
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Fig. 3-Combined lidoca ine dosage in a 70 kg patient with 
an initial IV injection of 100 mg followed immediately by 
an infusion of 52.8 µg / min/ kg body weight. The thin solid 
line shows the minimum effective concentration (MEC) 
for antiarrhythmic action. The thick solid line shows the 
concentration-time course resulting from combined therapy. 
The two interrupted lines show the concentration-time 
course which would have resulted from either mode of dos-
ing a lone. Note that this method maintains the plasma con-
centration in the effective range. 
reduced rate of lidocaine elimination. Also, lidocaine 
elimination can be reduced when hepatocellular func-
tion is severely impaired. When congestive failure 
or another condition reducing metabolism of the 
drug is present, infusion rates must be reduced 
accordingly-sometimes by as much as two or three-
fold. 
Intramuscular injection. This route of admin-
istration is still being studied for its therapeutic use-
fulness. The plasma concentration achieved after 
intramuscular injection seems to depend on the 
formulation and concentration injected, the partic-
ular muscle used for injection, activity in the muscle 
after injection, and general circulatory status. Using 
a special 10% solution and a 4 mg per kg body 
weight given in the deltoid muscle, we usually 
achieve a 1 p..g per ml plasma concentration by 5 
minutes, an average peak level of 3.3 µg per ml 
at 15 minutes, and the concentration exceeds 1 p..g 
per ml for 90 to 120 minutes (fig. 4). 
Oral doses. When lidocaine is given orally, it 
is well absorbed, but this route of administration 
has at least two disadvantages which severely limit 
its usefulness. First, the liver metabolizes an incredi-
ble proportion of an oral dose when the drug is 
presented to the liver via the portal circulation, 
and very low plasma concentrations of lidocaine are 
achieved. Second, oral doses tend to produce sig-
nificant abdominal discomfort and, very frequently, 
nausea. There is evidence to suggest that the nausea 
may be caused by the central action of a metabolite 
rather than local gastrointestinal irritation. 
Procainamide. Procainamide is a more versa-
tile drug than lidocaine not only because of its 
broader antiarrhythmic spectrum but also because 
it can be adminstered by more routes, including the 
oral route which permits long-term therapy. 
IV injection. There is a great deal of con-
flicting data in the literature regarding IV injection 
of procainamide. Many reports would lead one to 
believe that precipitous arterial hypotension is almost 
the rule after IV procainamide. T his is true if large 
injections are given. We have devised a simple 
method of IV injection which allows rapid control 
of ventricular rhythms but circumvents hypoten-
sion. We give 100 mg IV every five minutes. This 
leads to a linear rise in plasma drug concentra-
tion and progressive decrease in VPD's until they 
finally disappear. This usually takes 4 to 8 doses 
and is not accompanied by clinically significant 
hypotension ( fig. 5). Another advantage is that the 
physician knows immediately whether or not a par-
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Fig. 4- Average plasma lidocaine as a function of time in 
seven patients with acute myocardial infarction. Four mg/ 
kg body weight of 10% Jidocaine was injected in the deltoid 
muscle of seven patients during the initial eight hours of 
acute m yocardial infa rction. 
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ticular arrhythmia will respond to this agent and 
whether high or low concentrations will be required. 
Like lidocaine, procainamide plasma concentration 
falls rapidly after a single IV injection because of 
an initial rapid distribution of the drug into a large 
apparent volume (fig. 2). The late phase of decline 
in plasma concentration is due to elimination and 
has an average t112 of 3.5 hours. A large propor-
tion of procainamide is excreted unchaµged into the 
urine ( about 60%), but a significant amount is 
acetylated, presumably by the liver (25-30 % ). 
Intravenous constant-rate infusion. We have 
used this method for many years, particularly in 
the intensive care unit when a stable plasma con-
centration is desired . Figure 2 shows the plasma 
concentration of procainamide during and after an 
IV infusion . Because the MEC of procainamide is 
higher than lidocaine and the elimination t 11 2 is 
longer ( ± 3.5 hours) , infusions may not yield thera-
peutic concentrations until about 6 hours have 
elapsed, and 90 % of steady-state concentration 
is reached at 12 hours (3.3 x 3.5 ) . Because the 
elimination t112 of procainamide is about twice as 
long as that of lidocaine, the former drug takes 
longer to achieve a new steady state after a change 
in infusion rate and falls much slower when an 
infusion is stopped. Figure 4 shows the combination 
of intermittent IV injection therapy with constant-
rate infusion . 
Intramuscular injection. Procainamide is fairly 
well absorbed after IM injection and when given 
by this route rapidly produces antiarrhythmic plasma 
concentrations which decline as expected from its 
elimination t112 . The rate at which a MEC is 
achieved is not a great deal faster than after an 
oral dose. Therefore, unless the patient is unable 
to take the drug by mouth , there is little indication 
for IM administration. 
Oral doses. Procainamide can be given by 
mouth which is a major advantage over lidocaine. 
The drug is not well absorbed from the stomach 
when the pH is acid, and delay in gastric emptying 
can cause a delay in onset of absorption. However, 
this drug is quickly absorbed from the alkaline 
small intestine; after adequate doses, effective plasma 
levels are achieved in 15 minutes or so, and the 
peak level is achieved between 45 and 75 minutes 
after a dose. Absorption is virtually complete after 
90 to 105 minutes, and elimination takes place with 
a t1 ;2 of 3.5 to 4 hours. Renal excretion of procain-
amide is greatly reduced when the urine is alkaline, 
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Fig. 5-Plasma procainamide concentration plotted as a 
function of time when drug is given by incremental intra-
venous dosing and / or constant intravenous infusion. The 
minimum effecti ve concentration , MEC, is represented by 
the thin solid line. Six JOO mg doses of procainamide are 
given every 5 minutes , block dais, until the arrhythmia is 
completely suppressed at a plasma drug concentration of 
8.2 ftg / ml with in 30 minutes. The daslz-dot line shows the 
concentration-time course which wou ld have resulted if in-
cremental doses were stopped and no other mode of dosing 
started. Without prior injection , when a constant intravenous 
procainamide infusion ( 42.8 µg / min lkg body weight) is 
started , dashed curve, the plasma drug concentration would 
be above the MEC at 3 hours and is 6.5 µg / ml at steady 
state. The thick black line represents the plasma procaina-
mide concentration which would be obtained by initially 
giving the six l 00 mg injections and, then. immediately be-
ginnin g a constant IV infusion of 42.8 ftg / min / kg body 
weight. Note that the procainamide concentration never falls 
below the MEC. 
and in instances of congestive failure or renal failure. 
In these situations, a larger proportion of a given 
dose is acetylated by the liver. In congestive failure, 
procainamide, like lidocaine, has a smaller apparent 
volume of distribution, which means the same 
amount of drug in the body will result in a higher 
plasma drug concentration. Some years ago we noted 
procainamide toxicity occurring during the change 
from intravenous constant-rate infusions of procain-
amide to an oral regimen , even though the total 
24-hour doses were identical. Our error is shown 
in figure 6 (upper panel). Since an oral dose pro-
duces a rapid rise in plasma concentration, an initial 
oral dose given immediately on stopping the infusion 
causes a high (toxic) plasma concentration. It is 
apparent that an oral dose of a rapidly absorbed 
drug is tantamount to an TV injection. This unfor-
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Fig. 6-Changing from continuous intravenous infusion to 
an oral dose regimen of procainamide Vn = 140 liters, h 1,e = 
4.0 hours. 
The upper graph shows the termination of an intra-
venous infusion which for three days had maintained a 
stable plasma procainamide concentration of 8 µg/ ml. At 
time = 0, the infusion was discontinued and a regimen of 
1,000 mg oral doses every 6 hours was begun. Note that toxic 
concentrations are obtained after each of the first four oral 
doses although this will ultimately be a satisfactory regimen 
at steady state. 
The lower graph shows an identical patient, given an 
identical infusion and oral dosage regimen with only one 
exception-four hours were allowed to elapse between cessa-
tion of infusion and beginning the oral drug. Note that the 
plasma procainamide concentration never reaches toxic 
concentrations. 
tunate sequence can be avoided completely by 
waiting for about four hours after discontinuing the 
infusion before giving the first oral dose (fig. 6, 
lower panel). 
Toxicity. While antiarrhythmic drugs have 
considerably decreased mortality from arrhythmias 
seen following acute myocardial infarction and open 
heart surgery, improper use of these agents is as 
potentially life-threatening as the presence of the 
arrhythmia itself. A considerable incidence of tox-
icity is still encountered in using these drugs and 
impairs their general usefulness. Toxicity usually 
results from insufficient attention to the general 
physiologic state of the patient, the functional im-
pairment of the organs which metabolize these 
drugs, or pharmacodynamic considerations. How-
ever, even when errors in judgement are made using 
these drugs, a thorough knowledge of their toxic 
effects and a continuing careful search for early 
toxic signs can often prevent more severe and serious 
toxicity. 
Lidocaine. Clinical toxicity of lidocaine appears 
to be related to size of dose and rate of administra-
tion. Ordinary doses, however, may produce unde-
sirable effects when there is severe hepatic disorder, 
acidosis, severe congestive heart failure, low cardiac 
output, and shock. If lidocaine is infused at usual 
rates where these conditions exist, toxicity may 
ensue and, in fact, where blood levels have been 
measured in these cases, they are frequently two 
or three times higher than those needed for effective 
therapy. 
Lidocaine usually produces signs of central 
nervous system (CNS) iqvolvement before any sub-
jective or objective cardiovascular effects are ob-
served. The early symptoms may be extremely subtle. 
Blood levels greater than 6 µ.g per ml have been as-
sociated with dizziness, drowsiness, numbness of lips 
and tongue, speech disturbances, and psychosis. At 
present we suspect that many of the minor CNS 
symptoms of lidocaine toxicity go unrecognizecj. as 
such and are treated with diazepam or a similar agent. 
More severe CNS manifestations such as tremor, con-
vulsions, respiratory depression, and 11reflexia occur 
most commonly when venous blood levels of lidocaine 
are higher than 10 µ.g per ml but may be seen at 
lower concentrations. Signs of CNS toxicity may 
be treated by stopping lidocaine infusion and, as 
a rule, symptoms will improve within 15-30 min-
utes, but may take several hours to completely abate. 
Lidocaine-induced convulsions may require treat-
ment with small intravenous doses of short-acting 
barbiturates. High doses of barbiturate should be 
avoided since their CNS depressant effects may 
potentiate those of lidocaine and may result in 
respiratory arrest. 
The hemodynamic effects of 1 mg per kg of 
lidocaine injected intravenously have been measured 
by several groups. While hypotension may result 
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from larger doses of lidocaine, in therapeutic doses, 
there appears to be little effect on systemic arterial 
ressure, ventricular contractile force, cardiac out-
~ut heart rate, or stroke volume in man. Thus, it 
wo~ld seem that lidocaine given in this way exerts 
remarkably few if any adverse effects of clinical 
significance. The hemodynamic effects of lidocaine 
in the shock state or after a constant intravenous 
infusion are as yet unknown. 
Finally, lidocaine has been suspected of pro-
ducing cardiovascular toxicity. Clinical observations, 
largely unsubstantiated by conclusive evidence, have 
implicated lidocaine as the cause of: l) rapid ven-
tricular response to an atrial arrhythmia, 2) produc-
tion of ventricular arrhythmia, or increase in number 
of ectopic beats, 3) heart block, and 4) asystole. 
The use of lidocaine is not advised in the presence 
of heart block. 
Procainamide. Procainamide is more prone to 
produce direct cardiac toxicity expressed as altera-
tions in electrical and mechanical behavior of the 
heart than lidocaine. As with lidocaine, many of 
the toxic reactions seen with procainamide are 
related to size of dose and also to the route of 
administration. Rapid intravenous administration, 
particularly when given faster than 50-75 mg per 
minute, has been associated with undesirable electro-
cardiographic and hemodynamic effects. Because of 
this, oral and intramuscular use of procainamide has 
been advocated. However, even with these routes 
of administration and recommended dose size, tox-
icity may be encountered in congestive heart failure, 
renal disease, or shock. 
In our experience, therapeutic effectiveness and 
toxicity of procainamide are closely related to 
plasma drug concentration. We consider the effec-
tive antiarrhythmic plasma drug concentration range 
to be 3 or 4-10 µ,g per ml and have observed electro-
~hysiologic and hemodynamic toxicity at concentra-
tions greater than 12 µ,g per ml. Notwithstanding 
the bad reputation of intravenously administered 
procainamide, we have found that antiarrhythmic 
plasma drug concentrations are attained rapidly, 
~afely, and predictably when procainamide is given 
int~avenously. We recommend 100 mg of procain-
amide be given intravenously every 5 minutes with 
electrocardiographic and blood pressure monitoring. 
An example of this method is shown in figure 4 · 
the I . ' 
e ectrocard1ogram was continuously monitored 
and p r . 
a 1ent P.B. was given l 00 mg of procainamide 
every 5 minutes until VPD's were abolished. Plasma 
samples taken 41/2 minutes after each dose indicate 
there is a direct linear relationship between cumula-
tive dose and plasma drug concentration. Moreover, 
after each procainamide injection, the number of 
VPD's diminishes until the sixth dose when the 
arrhythmia is completely abolished and a plasma 
drug concentration within the therapeutic range 
( 8.3 µ,g per ml) is achieved. Neither untoward 
hemodynamic nor electrocardiographic effects were 
encountered during the course of treatment. 
Even at low plasma drug concentration range, 
procainamide produces electrocardiographic changes 
resulting from its cardiac electrophysiologic actions. 
The P-R, QRS, and QT intervals are all prolonged 
at therapeutic plasma concentrations. In addition, 
toxic drug concentrations have been associated with 
progression of these or appearance of more dramatic 
electrophysiologic effects such as : l) suppression 
of cardiac automaticity, including the S-A node, lead-
ing to asystole, 2) impairment of A-V conduction, 
leading to heart block, and 3) slowing of intra-
ventricular conduction greater than 30%. Another 
noteworthy undesirable electrocardiographic change 
stems from the fact that toxic concentrations of 
procainamide almost invariably cause increased 
automaticity and multifocal pacemaker activity in 
isolated cardiac Purkinje fibers. Thus, the appear-
ance of ectopic ventricular beats, ventricular tachy-
cardia, or fibrillation in a patient who presumably 
has achieved therapeutic drug concentration may 
not represent arrhythmia breakthrough but rather 
procainamide toxicity. If the physician is unaware 
of this complication, he may continue to administer 
procainamide or even increase the dose, not real-
izing that the drug is responsible for evoking the 
arrhythmia. Since therapeutic and toxic drug effects 
are so well correlated with electrocardiographic 
changes, the electrocardiogram is an excellent way 
to monitor procainamide efficacy and, when care-
fully used, the incidence of toxicity is likely to be 
reduced. Because of its depressant effects on A-V 
conduction and ventricular automaticity, procain-
amide is contraindicated in heart block, and cautious 
use has been advised in patients with wide QRS 
intervals and bundle branch block. 
Procainamide may produce hemodynamic 
changes by depressing myocardial contractility and 
the cardiac output and thereby produce hypotension. 
While the severity of these hemodynamic alterations 
appears to be related to dose size and rate of admin-
istration, they may be further intensified by heart 
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disease and congestive heart failure. Although pro-
cainamide should be used cautiously in these condi-
tions, they do not preclude therapy. We have noted 
that the probability of untoward hemodynamic 
effects is minimized by intermittent intravenous in-
jections and by careful monitoring of blood pressure. 
If necessary, doses higher than 1000 mg may be 
given by this technique without evidence of cardiac 
toxicity or hypotension. Procainamide-induced he-
modynamic or electrocardiographic toxicity may be 
treated by molar sodium lactate and the catechol-
amines, norepinephrine or isoproterenol. 
Extracardiac toxic reactions to procainamide 
are most commonly seen during chronic oral 
therapy. Gastrointestinal disturbances (nausea, vom-
iting, diarrhea), and CNS disturbances (mental de-
pression, psychosis, and convulsions) have been 
reported. Other toxic effects include skin rash, fever 
and chills, and agranulocytosis. Most of these extra-
cardiac reactions subside almost immediately with 
discontinuation of the drug, but some may persist 
a few days to a few weeks. A syndrome resembling 
systemic lupus erythematosis (SLE) characterized 
by arthralgia, fever, pleuropneumonic involvement, 
and hepatomegaly has occurred frequently in pa-
tients on long-term maintenance therapy. Rarely, 
adrenal corticosteroids have been required to con-
trol unusually tenacious symptoms of SLE. It should 
be pointed out that, unlike SLE, the drug induced 
SLE-like syndrome produces no permanent damage 
in any vital organ system. This and the fact that 
aspirin or steroids may control symptoms are im-
portant considerations in planning the management 
of a patient who has a life-threatening arrhythmia 
for which other drugs are ineffective, and who has 
developed the SLE-like syndrome. In such a case, 
one reasonable course of action is to continue pro-
cainamide and control symptoms of the SLE syn-
drome with salicylates or adrenal corticosteroids. 
